Compare ZURA & CLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZURA | CLB |
|---|---|---|
| Founded | 2022 | 1936 |
| Country | United States | United States |
| Employees | N/A | 3300 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.4M | 414.2M |
| IPO Year | 2021 | 2023 |
| Metric | ZURA | CLB |
|---|---|---|
| Price | $0.97 | $7.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | $8.00 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 6.7M | 644.2K |
| Earning Date | 10-27-2026 | 10-28-2026 |
| Dividend Yield | N/A | ★ 0.48% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.23 |
| Revenue | N/A | ★ $526,520,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.52 |
| P/E Ratio | ★ N/A | $36.57 |
| Revenue Growth | N/A | ★ 0.51 |
| 52 Week Low | $0.92 | $8.12 |
| 52 Week High | $7.25 | $20.36 |
| Indicator | ZURA | CLB |
|---|---|---|
| Relative Strength Index (RSI) | 24.64 | 24.32 |
| Support Level | $0.93 | N/A |
| Resistance Level | $5.97 | $10.76 |
| Average True Range (ATR) | 0.23 | 0.42 |
| MACD | -0.15 | -0.10 |
| Stochastic Oscillator | 0.46 | 3.59 |
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
Core Laboratories Inc is a providers of proprietary and patented reservoir description and production enhancement services and products to the oil and gas industry, through client relationships. The company operates its business in two segments; Reservoir Description, and Production Enhancement. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services. The company generates majority of its revenue from Reservoir Description segment.